NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor

Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark

TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strategic and institutional experience surrounding the Company as NetraMark advances its commercialization strategy.